BioTech

Todos Medical Ltd. a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced that it has received approval from the Israeli Ministry of Health (AMAR) to...

Teva Pharmaceutical has entered into a settlement with the State of Oklahoma over the company's marketing of Opioid drugs. Although Teva has not admitted any wrongdoing, it has agreed to pay a fine of $85 million to settle all outstanding claims against...

Teva Pharmaceuticals has reached a settlement with Cuyahoga and Summit counties of Ohio to settle claims in the Opioid addiction lawsuit. Under the terms of the settlement, Teva will provide buprenorphine-naloxone (sublingual tablets), known by the brand name Suboxone®, valued at $25...

Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Tarceva®1 (erlotinib) tablets, 100 and 150 mg, in the U.S. Erlotinib Tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung...

Teva Pharmaceutical Industries Ltd reported third-quarter results that were better than expected by analysts. It also appointed Eli Kalif as Executive Vice President and Chief Financial Officer. Revenues in the third quarter of 2019 were $4,264 million,...

Foamix Pharmaceuticals Ltd. received U.S. Food and Drug Administration (FDA) approval for its  AMZEEQTM (minocycline) topical foam, 4%. AMZEEQ, provides treatment for inflammatory lesions caused by non-nodular moderate to severe acne vulgaris in adults and pediatric patients (age 9 and older). This...

Teva Pharmaceutical received excellent news today, when it was reported the company had reached a tentative agreement with the State of Ohio for its part in the Opioid crisis. The settlement was for $10 million, a sum much below the expectations of...

CEO Nadav Kidron Oramed Pharmaceuticals Inc.(www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive agreements to form a joint venture focused on the development of novel oral COVID-19 vaccines.  The...

2021 business outlook:Revenues are expected to be $16.4 - $16.8 billion (2020 actual results include ~$240 million in revenues from generic products in Japan divested on February 1, 2021, along with a manufacturing site)Non-GAAP EPS is expected to be $2.50 - $2.70Free...

Haifa, Israel, October 3, 2021 – Elbit Systems Ltd. (NASDAQ: ESLT and TASE: ESLT) ("Elbit Systems") announced today that its subsidiaries, Beyeonics Surgical Ltd. (“Beyeonics Surgical”) and Beyeonics Vision Ltd. (“Beyeonics Vision”), concluded a financing round in an aggregate amount of $36 million. The financing round is...